OTLC
Oncotelic Therapeutics, Inc.
Price Chart
Latest Quote
$0.05
+0.00 (+0.00%)
Current Price
| Previous Close | $0.05 |
| Open | $0.05 |
| Day High | $0.05 |
| Day Low | $0.05 |
| Volume | 222,888 |
Stock Information
| Shares Outstanding | 444.50M |
| Total Debt | $14.31M |
| Cash Equivalents | $64K |
| Net Income | $247.38M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $22.22M |
| P/E Ratio | 0.08 |
| EPS (TTM) | $0.59 |
| Exchange | OQB |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $34.71M |
| Income | $247.38M |
| Book/sh | $0.59 |
| Cash/sh | $0.00 |
| Employees | 38 |
Financial Ratios
| Quick Ratio | 0.00 |
| Current Ratio | 0.11 |
| Debt/Eq | 5.46 |
Returns & Margins
| ROA | -1.41% |
| ROE | 183.49% |
Ownership
| Insider Ownership | 48.45% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| PEG | 1.05 |
| P/B | 0.08 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.05 |
| SMA50 | $0.05 |
| SMA200 | $0.07 |
| RSI | 33.33 |
| ATR | 0.0050 |
| Shares Float | 228.43M |
| Short Float | 2.50% |
| Short Ratio | 8.04 |
| Rel Volume | 1.39 |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | +25.00% |
| 6 Months | -44.44% |
| YTD | -37.50% |
| Year | +0.00% |
| 3 Years | +66.67% |
| 5 Years | -80.77% |
| 10 Years | -93.83% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.05 | 339,900 |
| 2026-06-17 | $0.05 | 400,300 |
| 2026-06-16 | $0.04 | 202,500 |
| 2026-06-15 | $0.04 | 141,800 |
| 2026-06-12 | $0.05 | 244,400 |
| 2026-06-11 | $0.05 | 265,300 |
| 2026-06-10 | $0.05 | 57,600 |
| 2026-06-09 | $0.05 | 64,500 |
| 2026-06-08 | $0.05 | 172,500 |
| 2026-06-05 | $0.05 | 71,400 |
| 2026-06-04 | $0.05 | 93,000 |
| 2026-06-03 | $0.05 | 272,200 |
| 2026-06-02 | $0.05 | 685,700 |
| 2026-06-01 | $0.06 | 78,500 |
| 2026-05-29 | $0.06 | 131,400 |
| 2026-05-28 | $0.06 | 724,500 |
| 2026-05-27 | $0.06 | 123,300 |
| 2026-05-26 | $0.06 | 363,700 |
| 2026-05-22 | $0.06 | 210,500 |
| 2026-05-21 | $0.06 | 230,500 |
| 2026-05-20 | $0.05 | 251,500 |
| 2026-05-19 | $0.05 | 184,500 |
About Oncotelic Therapeutics, Inc.
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications in the United States. The company develops antisense and small molecule injectable drugs for the treatment of cancer. It is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-Ã2, which is in phase 3 clinical trials for pancreatic cancer, melanoma, and glioblastoma, as well as for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. In addition, the company develops CA4P for the treatment of advanced metastatic melanoma; AL-101, an intranasal drug and delivery system for intra-nasal apomorphine for the treatment of parkinson's disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of support technologies, as well as nanoparticle products for the treatment of various cancers. The company is based in Agoura Hills, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on OTLC.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $70,000 | $0 | $0 |
| Operating Revenue | $0 | $70,000 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $857,723 | $1,044,786 | $2,971,046 | $2,002,813 |
| Total Expenses | $376,013 | $634,869 | $5,610,574 | $9,125,883 |
| Other Income Expense | $-3,545,723 | $-6,596,410 | $13,258,223 | $611,406 |
| Other Non Operating Income Expenses | $22,937 | $72,246 | $533,485 | - |
| Net Non Operating Interest Income Expense | $-857,723 | $-1,044,786 | $-2,971,046 | $-2,002,813 |
| Interest Expense Non Operating | $857,723 | $1,044,786 | $2,971,046 | $2,002,813 |
| Operating Expense | $376,013 | $634,869 | $5,610,574 | $9,125,883 |
| General And Administrative Expense | $376,013 | $573,726 | $4,853,664 | $5,467,266 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-4,523,932 | $-7,903,093 | $5,094,981 | $-9,391,042 |
| Net Interest Income | $-857,723 | $-1,044,786 | $-2,971,046 | $-2,002,813 |
| Normalized Income | $-955,272 | $-1,234,437 | $-4,957,562 | $-10,002,448 |
| Net Income From Continuing And Discontinued Operation | $-4,523,932 | $-7,903,093 | $5,094,981 | $-9,391,042 |
| Total Operating Income As Reported | $-3,576,013 | $-6,648,015 | $-9,721,653 | $-9,125,883 |
| Net Income Common Stockholders | $-4,523,932 | $-7,903,093 | $5,094,981 | $-9,391,042 |
| Net Income | $-4,523,932 | $-7,903,093 | $5,094,981 | $-9,391,042 |
| Net Income Including Noncontrolling Interests | $-4,779,459 | $-8,206,065 | $4,676,603 | $-10,517,290 |
| Net Income Continuous Operations | $-4,779,459 | $-8,206,065 | $4,676,603 | $-10,517,290 |
| Pretax Income | $-4,779,459 | $-8,206,065 | $4,676,603 | $-10,517,290 |
| Special Income Charges | $-3,288,258 | $-6,456,288 | $12,582,588 | $319,257 |
| Operating Income | $-376,013 | $-564,869 | $-5,610,574 | $-9,125,883 |
| Per Share | ||||
| Diluted EPS | $-0.01 | $-0.02 | $0.01 | $-0.03 |
| Basic EPS | $-0.01 | $-0.02 | $0.01 | $-0.03 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $2,672,195 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-353,076 | $-492,623 | $-5,064,248 | $-9,064,370 |
| Total Unusual Items | $-3,568,660 | $-6,668,656 | $12,724,738 | $611,406 |
| Total Unusual Items Excluding Goodwill | $-3,568,660 | $-6,668,656 | $12,724,738 | $611,406 |
| EBITDA (Bullshit earnings) | $-3,921,736 | $-7,161,279 | $7,660,490 | $-8,452,964 |
| EBIT | $-3,921,736 | $-7,161,279 | $7,647,649 | $-8,514,477 |
| Diluted Average Shares | $404,396,473 | $384,075,369 | $457,299,890 | $303,078,548 |
| Basic Average Shares | $404,396,473 | $384,075,369 | $384,075,369 | $303,078,548 |
| Diluted NI Availto Com Stockholders | $-4,523,932 | $-7,903,093 | $5,094,981 | $-9,391,042 |
| Minority Interests | $255,527 | $302,972 | $418,378 | $1,126,248 |
| Other Special Charges | $88,258 | $373,142 | $257,810 | $-319,257 |
| Impairment Of Capital Assets | $3,200,000 | $6,083,146 | $4,111,079 | $0 |
| Gain On Sale Of Security | $-280,402 | $-212,368 | $142,150 | $292,149 |
| Research And Development | $0 | $61,143 | $756,910 | $3,658,617 |
| Selling General And Administration | $376,013 | $573,726 | $4,853,664 | $5,467,266 |
| Other Gand A | $376,013 | $573,726 | $4,853,664 | $5,467,266 |
| Reconciled Depreciation | - | $0 | $12,841 | $61,513 |
| Gain On Sale Of Ppe | - | $0 | $16,951,477 | $0 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $4,361,641 | $5,040,139 | $6,235,896 | $-15,030,383 |
| Total Assets | $26,677,426 | $30,014,952 | $36,116,819 | $23,613,351 |
| Total Non Current Assets | $26,543,215 | $29,743,215 | $35,813,655 | $22,986,056 |
| Investmentin Financial Assets | $22,653,225 | $22,653,225 | $22,640,519 | $0 |
| Goodwill And Other Intangible Assets | $3,889,990 | $7,089,990 | $13,173,136 | $22,986,056 |
| Other Intangible Assets | $1,101,760 | $1,101,760 | $1,101,760 | $1,923,601 |
| Current Assets | $134,211 | $271,737 | $303,164 | $627,295 |
| Other Current Assets | $9,107 | $62,356 | $21,964 | $18,778 |
| Restricted Cash | $20,000 | $20,000 | $20,000 | $20,000 |
| Receivables | $18,976 | $18,976 | $19,748 | $19,748 |
| Accounts Receivable | $18,976 | $18,976 | $19,748 | $19,748 |
| Cash Cash Equivalents And Short Term Investments | $86,128 | $170,405 | $241,452 | $568,769 |
| Cash And Cash Equivalents | $86,128 | $170,405 | $241,452 | $568,769 |
| Cash Financial | $86,128 | $170,405 | $241,452 | $568,769 |
| Prepaid Assets | - | - | - | $18,778 |
| Debt | ||||
| Net Debt | $13,001,946 | $12,403,376 | $11,015,519 | $8,424,715 |
| Total Debt | $13,088,074 | $12,573,781 | $11,256,971 | $8,993,484 |
| Current Debt And Capital Lease Obligation | $13,088,074 | $10,675,313 | $11,256,971 | $8,993,484 |
| Current Debt | $13,088,074 | $10,675,313 | $11,256,971 | $8,993,484 |
| Other Current Borrowings | $13,088,074 | $10,675,313 | $11,256,971 | $8,993,484 |
| Long Term Debt And Capital Lease Obligation | - | $1,898,468 | - | - |
| Long Term Debt | - | $1,898,468 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $19,199,914 | $18,403,415 | $16,923,407 | $15,454,920 |
| Total Non Current Liabilities Net Minority Interest | $0 | $1,898,468 | $0 | $0 |
| Current Liabilities | $19,199,914 | $16,504,947 | $16,923,407 | $15,454,920 |
| Other Current Liabilities | $3,328,616 | $3,048,214 | $2,823,140 | $2,965,290 |
| Payables And Accrued Expenses | $2,783,224 | $2,781,420 | $2,843,296 | $3,496,146 |
| Payables | $2,037,782 | $2,000,712 | $2,068,196 | $2,331,172 |
| Accounts Payable | $1,691,725 | $1,656,613 | $1,735,764 | $1,927,749 |
| Equity | ||||
| Common Stock Equity | $8,251,631 | $12,130,129 | $19,409,032 | $7,955,673 |
| Total Equity Gross Minority Interest | $7,477,512 | $11,611,537 | $19,193,412 | $8,158,431 |
| Stockholders Equity | $8,251,631 | $12,130,129 | $19,409,032 | $7,955,673 |
| Retained Earnings | $-38,040,668 | $-33,516,736 | $-25,926,069 | $-31,021,050 |
| Other | ||||
| Ordinary Shares Number | $407,289,618 | $399,184,128 | $391,846,880 | $375,288,146 |
| Share Issued | $407,289,618 | $399,184,128 | $391,846,880 | $375,288,146 |
| Tangible Book Value | $4,361,641 | $5,040,139 | $6,235,896 | $-15,030,383 |
| Invested Capital | $21,339,705 | $24,703,910 | $30,666,003 | $16,949,157 |
| Working Capital | $-19,065,703 | $-16,233,210 | $-16,620,243 | $-14,827,625 |
| Total Capitalization | $8,251,631 | $14,028,597 | $19,409,032 | $7,955,673 |
| Minority Interest | $-774,119 | $-518,592 | $-215,620 | $202,758 |
| Additional Paid In Capital | $42,219,400 | $41,655,026 | $41,416,632 | $35,223,842 |
| Capital Stock | $4,072,899 | $3,991,839 | $3,918,469 | $3,752,881 |
| Common Stock | $4,072,899 | $3,991,839 | $3,918,469 | $3,752,881 |
| Current Accrued Expenses | $745,442 | $780,708 | $775,100 | $1,164,974 |
| Dueto Related Parties Current | $346,057 | $344,099 | $332,432 | $403,423 |
| Investments And Advances | $22,653,225 | $22,653,225 | $22,640,519 | $0 |
| Available For Sale Securities | $22,653,225 | $22,653,225 | $22,640,519 | - |
| Goodwill | $2,788,230 | $5,988,230 | $12,071,376 | $21,062,455 |
| Preferred Shares Number | - | - | $6,000 | $6,000 |
| Preferred Stock | - | - | $0 | $0 |
| Line Of Credit | - | - | - | $0 |
| Net PPE | - | - | - | $0 |
| Accumulated Depreciation | - | - | - | $-111,958 |
| Gross PPE | - | - | - | $111,958 |
| Other Properties | - | - | - | $111,958 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-740,267 | $-1,321,047 | $-1,452,562 | $-4,434,465 |
| Operating Activities | ||||
| Operating Cash Flow | $-740,267 | $-1,321,047 | $-1,452,562 | $-4,434,465 |
| Cash Flow From Continuing Operating Activities | $-740,267 | $-1,321,047 | $-1,452,562 | $-4,434,465 |
| Operating Gains Losses | $280,402 | $225,074 | $-14,188,311 | $1,551,217 |
| Financing Activities | ||||
| Financing Cash Flow | $656,000 | $1,250,000 | $1,125,245 | $4,529,215 |
| Cash Flow From Continuing Financing Activities | $656,000 | $1,250,000 | $1,125,245 | $4,529,215 |
| Net Common Stock Issuance | $0 | $-125,000 | $158,820 | $1,965,345 |
| Repurchase Of Capital Stock | - | $-125,000 | $0 | - |
| Issuance Of Capital Stock | - | $0 | $158,820 | $1,965,345 |
| Net Other Financing Charges | - | $-35,000 | - | $-2,005 |
| Common Stock Issuance | - | $0 | $158,820 | $1,965,345 |
| Other | ||||
| Issuance Of Debt | $656,000 | $1,410,000 | $966,425 | $2,973,375 |
| Interest Paid Supplemental Data | $365,940 | $390,561 | $397,995 | $299,365 |
| Income Tax Paid Supplemental Data | $1,600 | $1,600 | $0 | $0 |
| End Cash Position | $106,128 | $190,405 | $261,452 | $588,769 |
| Beginning Cash Position | $190,405 | $261,452 | $588,769 | $494,019 |
| Changes In Cash | $-84,277 | $-71,047 | $-327,317 | $94,750 |
| Net Issuance Payments Of Debt | $656,000 | $1,410,000 | $966,425 | $2,565,875 |
| Net Short Term Debt Issuance | $656,000 | $1,410,000 | $0 | $2,565,875 |
| Short Term Debt Issuance | $656,000 | $1,410,000 | $0 | $2,973,375 |
| Change In Working Capital | $348,391 | $-86,327 | $799,774 | $305,254 |
| Change In Payables And Accrued Expense | $295,142 | $-45,935 | $802,960 | $222,163 |
| Change In Payable | $295,142 | $-45,935 | $802,960 | $222,163 |
| Change In Account Payable | $295,142 | $-45,935 | $802,960 | $222,163 |
| Change In Prepaid Assets | $53,249 | $-40,392 | $-3,186 | $83,091 |
| Other Non Cash Items | $210,399 | $675,059 | $2,233,311 | $1,901,526 |
| Unrealized Gain Loss On Investment Securities | $0 | $-12,706 | $0 | - |
| Asset Impairment Charge | $3,200,000 | $6,083,918 | $4,111,079 | $1,500,000 |
| Gain Loss On Investment Securities | $280,402 | $225,074 | $2,763,166 | $1,897,978 |
| Net Income From Continuing Operations | $-4,779,459 | $-8,206,065 | $4,676,603 | $-10,517,290 |
| Common Stock Payments | - | $-125,000 | $0 | - |
| Net Long Term Debt Issuance | - | $0 | $966,425 | $2,308,820 |
| Long Term Debt Issuance | - | $0 | $966,425 | $2,716,320 |
| Stock Based Compensation | - | $0 | $902,141 | $763,315 |
| Depreciation Amortization Depletion | - | $0 | $12,841 | $61,513 |
| Depreciation And Amortization | - | $0 | $12,841 | $61,513 |
| Amortization Cash Flow | - | $0 | $12,841 | $51,365 |
| Amortization Of Intangibles | - | $0 | $12,841 | $51,365 |
| Repayment Of Debt | - | - | $0 | $-407,500 |
| Short Term Debt Payments | - | - | $0 | $-407,500 |
| Long Term Debt Payments | - | - | $0 | $-407,500 |
| Depreciation | - | - | $0 | $10,148 |
Fetched: 2026-02-02